Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two-Drug cocktail aims to tame stubborn Crohn's disease

NCT ID NCT07697547

Completed Disease control Sponsor: Shanghai 10th People's Hospital Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study looks at whether combining two drugs—upadacitinib and ustekinumab—at lower doses can help people with Crohn's disease that hasn't improved with standard treatments. Participants are adults aged 18 to 65 who have already tried and failed other therapies. The goal is to see if the combination can bring the disease under control and reduce gut inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
upadacitinib and ustekinumab
What this could lead to
If successful, this combination could offer a new treatment option for people with Crohn's disease who have not responded to other therapies.
What could go wrong
This is a small, retrospective study, not a large controlled trial, so results may not apply broadly. Combining two immune-suppressing drugs may increase infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE INFLAMMATORY BOWEL DISEASE (IBD)

Contacts and locations

Locations

  • The Tenth People's Hospital of Shanghai

    Shanghai, Shanghai Municipality, 201505, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.